Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice

Fineline Cube Apr 18, 2025

US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to...

Company Deals Medical Device

Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device

Fineline Cube Apr 18, 2025

China-based Junion Therapeutics (Xiamen) Co., Ltd has reportedly secured RMB 100 million (USD 13.7 million)...

Company Deals Drug

Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies

Fineline Cube Apr 18, 2025

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with...

Company Drug

Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer

Fineline Cube Apr 18, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment

Fineline Cube Apr 18, 2025

UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK) has announced the receipt of...

Company Drug

Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review

Fineline Cube Apr 18, 2025

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...

Company Drug

Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA

Fineline Cube Apr 18, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Drug

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors

Fineline Cube Apr 17, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has received clinical trial approval from...

Company Drug

Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 17, 2025

China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to Beijing Avistone...

Company Deals

Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration

Fineline Cube Apr 17, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has announced the completion of...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments

Fineline Cube Apr 17, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...

Company Drug

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease

Fineline Cube Apr 17, 2025

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...

Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Fineline Cube Apr 17, 2025

China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...

Company Drug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Fineline Cube Apr 17, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...

Company Deals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion

Fineline Cube Apr 17, 2025

Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Deals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Fineline Cube Apr 17, 2025

China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...

Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Fineline Cube Apr 17, 2025

President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...

Company Drug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Fineline Cube Apr 16, 2025

Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...

Posts pagination

1 … 172 173 174 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.